Evolent Health has announced the divestiture of its Evolent Care Partners division to Privia Health Group in a transaction valued at up to $113 million. The healthcare company’s shares experienced initial volatility following the news, declining 2.33 percent to $8.39 before recovering with a 2.09 percent gain in after-hours trading.
Strategic Focus on Specialty Care
The sale marks a significant strategic pivot for Evolent Health, enabling the company to concentrate resources on its core specialty care business. This segment focuses on value-based treatment for complex conditions such as cancer and cardiovascular disease. The divested primary care unit currently manages care for more than 120,000 members through various programs, including Medicare Advantage and commercial health plans.
Transaction specifics include an immediate cash payment of $100 million upon closure, with an additional performance-based component of up to $13 million. This contingent payment is tied to results in the Medicare Shared Savings Program for 2025. The deal is anticipated to finalize during the fourth quarter of 2025, with projected positive contributions to adjusted EBITDA beginning in 2026.
Should investors sell immediately? Or is it worth buying Evolent Health?
Building on Recent Financial Performance
This strategic move follows Evolent Health’s recent strong financial showing. The company reported second-quarter 2025 adjusted EBITDA of $37.5 million, meeting the upper end of its forecast range. Management has reaffirmed its full-year guidance, projecting revenue between $2.06 billion and $2.11 billion alongside adjusted EBITDA of $135 million to $165 million.
The portfolio optimization strategy extends beyond this divestiture. Evolent Health has recently renegotiated three performance-based contracts specifically designed to address rising oncology care costs. These renegotiations are expected to boost 2025 profits by approximately $115 million.
Technology and Future Outlook
Concurrently, Evolent Health is accelerating its artificial intelligence initiatives with an ambitious target: automating 80 percent of all authorization requests within a 24-month timeframe. Market participants are awaiting the company’s upcoming quarterly results, scheduled for release on November 6, 2025, for further insight into the progress of this comprehensive strategic repositioning.
Ad
Evolent Health Stock: Buy or Sell?! New Evolent Health Analysis from September 25 delivers the answer:
The latest Evolent Health figures speak for themselves: Urgent action needed for Evolent Health investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 25.
Evolent Health: Buy or sell? Read more here...
